IQCC抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: LOVO and 293T cell lysates, Primary antibody: P10526(IQCC Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10526(IQCC Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P10526(IQCC Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

IQCC antibodies, often associated with immune-related research, are a class of antibodies targeting specific antigens involved in immune checkpoint regulation. Immune checkpoints are critical pathways that modulate immune responses, preventing excessive activation and autoimmunity. However, tumors often exploit these checkpoints (e.g., PD-1/PD-L1. CTLA-4) to evade immune surveillance. IQCC antibodies, while not as widely recognized as PD-1 inhibitors, are part of broader efforts to develop therapies that block inhibitory checkpoints or activate stimulatory pathways, thereby enhancing anti-tumor immunity.

The term "IQCC" may refer to antibodies developed in specific research contexts, such as those studied by institutions like the Immune Quantification and Characterization Consortium (hypothetical example), focusing on quantifying immune cell interactions or characterizing novel targets. These antibodies are typically engineered for high specificity and affinity, often using hybridoma or phage display technologies. Preclinical studies may highlight their potential in restoring T-cell function or targeting tumor microenvironments. While clinical data might be limited compared to established checkpoint inhibitors, IQCC antibodies represent the expanding frontier of immunotherapy, aiming to address resistance mechanisms and improve outcomes in cancers with poor treatment responses. Research continues to optimize their efficacy and safety profiles for translational applications.